Thanks, Rob, and good morning, everyone. I'd like to remind everyone that with the sale of Klein, those operations have been treated as discontinued operations. Prior period results have been restated to reflect that. Accordingly, the results from continuing operations that we reported yesterday, and are discussing here today, including prior period comparative data, do not include amounts related to Klein. They include only our ongoing business. As Rob mentioned earlier, revenues from Marine Technology Products sales totaled approximately $13.4 million in the quarter, which was up about 51% from approximately $8.9 million in the same period a year ago. Full year revenue amounted to $36.5 million, which was up approximately 46% over the previous year, and represents the highest annual revenue ever reported by our Seamap business. Our fourth quarter results benefited from a little over $5 million of orders that were delayed from the third quarter, but there were other orders pushed from the fourth quarter into fiscal 2025. The shifting of deliveries and the impact of that on quarterly revenues, is just a fact of life for our business. We continue to believe the strength we are seeing in all our key markets and the growth in our backlog of orders positions us well, for sustained high-level revenue in the coming quarters. Full year gross profit from continuing operations was approximately $16 million, which was up approximately 61%, when compared to the prior year. This represents a gross profit margin of approximately 44% for the year. This is an improvement from the 40% gross profit margin, achieved in fiscal 2023. Incremental year-over-year revenue resulted in greater operating efficiency, and overhead absorption and a much improved gross profit margin. Our general and administrative expenses, were approximately $3 million for the fourth quarter, which was roughly in line with the $2.9 million, from the third quarter. As we mentioned in our last call, the sale of Klein is allowing us to streamline our operations, and thereby reduce some costs. It's important to note that, we typically experience higher G&A spending levels in the fourth quarter, associated with year-end activities. We believe mask a bit of the Klein-related savings, achieved during the quarter. We do anticipate realizing additional cost savings benefits in fiscal 2025. Our research and development expense for the fourth quarter, which relates only to our continuing operations, was $654,000. That was up both sequentially and compared to the prior year period. These costs are largely directed toward the development of our next generation streamer system, and continued development of our Spectral Ai Software Suite. Operating income for the fourth quarter was $2.3 million, compared to an operating loss of approximately $1.5 million in the third quarter, and operating income of $595,000 in the fourth quarter of fiscal 2023. Our fourth quarter adjusted EBITDA from continuing operations was $2.6 million, compared to $1.5 million in the fourth quarter a year ago. Adjusted EBITDA from continuing operations for fiscal 2024, was approximately $2.3 million, compared to a loss of $3.4 million in fiscal 2023. Net income for the fourth quarter was approximately $1.4 million, which was over 100% improvement from the $666,000, reported in the fourth quarter of fiscal 2023. Total net income for fiscal 2024, was $274,000, compared to a loss of $8.8 million in fiscal 2023. As Rob mentioned, we're pleased to have achieved profitability in fiscal 2024, something that hasn't been done in many years, and we hope to continue building on this momentum in future periods. As of January 31, 2024, we had working capital of approximately $18.1 million and approximately $5.3 million of cash on hand. MIND's liquidity position is significantly improved, and the balance sheet remained strong following the sale of Klein in August, which enabled the company to eliminate the outstanding high cost debt. As of today, MIND is debt free. I'll now pass it back over to Rob, for some concluding comments.